Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2011; 17(41): 4607-4613
Published online Nov 7, 2011. doi: 10.3748/wjg.v17.i41.4607
Published online Nov 7, 2011. doi: 10.3748/wjg.v17.i41.4607
Table 1 Baseline characteristics of all patients (n = 98)
| Characteristic | Value |
| Age (yr) | 36.0 ± 10.6 |
| Male | 52 (53) |
| Activity grade | |
| Absent (A0) | 32 (33) |
| Mild (A1) | 40 (41) |
| Moderate (A2) | 20 (20) |
| Severe (A3) | 6 (6) |
| Fibrosis stage | |
| No fibrosis (F0) | 21 (20) |
| Portal fibrosis without septa (F1) | 35 (36) |
| Portal fibrosis with rare septa (F2) | 29 (30) |
| Numerous septa without cirrhosis (F3) | 10 (10) |
| Cirrhosis (F4) | 3 (3) |
Table 2 Univariate analysis for significant and minimal disease
| Significant1(n = 46) | Minimal(n = 52) | P value | |
| Age (yr) | 39.6 ± 11.4 | 32.9 ± 8.7 | 0.002 |
| Gender | 0.15 | ||
| Male | 28 (61) | 24 (46) | |
| Female | 18 (39) | 28 (56) | |
| Bilirubin total (mg/dL) | 0.62 ± 0.34 | 0.49 ± 0.30 | 0.04 |
| Bilirubin direct (mg/dL) | 0.21 ± 0.17 | 0.15 ± 0.08 | 0.04 |
| ALT (U/L) | 53.2 ± 39.2 | 32.60 ± 15.90 | 0.002 |
| ALP (U/L) | 80.4 ± 26.9 | 81.70 ± 32.30 | 0.78 |
| GGT (U/L) | 51.8 ± 47.2 | 23.80 ± 16.90 | < 0.001 |
| Haptoglobin (g/L) | 1.05 ± 0.45 | 1.05 ± 0.49 | 0.99 |
| A2M (g/L) | 2.56 ± 0.64 | 2.24 ± 0.55 | 0.009 |
| Apo-A1 (mg/dL) | 96.85 ± 23.70 | 114.2 ± 29.80 | 0.002 |
| Hydroxyproline (μmol/L) | 9.7 ± 7.0 | 13.5 ± 9.30 | 0.03 |
| Proline (μmol/L) | 123.0 ± 78.10 | 144.2 ± 106.4 | 0.27 |
| Hyaluronic acid (ng/mL) | 100 ± 150 | 23.90 ± 16.40 | 0.001 |
Table 3 Scores of six marker indices with their coordinate liverscores
| 6 marker | Liverscore | 6 marker | Liverscore | 6 marker | Liverscore |
| -2.149 | 0.00 | -0.883 | 0.34 | 0.270 | 0.68 |
| -1.985 | 0.01 | -0.869 | 0.35 | 0.277 | 0.69 |
| -1.894 | 0.02 | -0.855 | 0.36 | 0.364 | 0.70 |
| -1.878 | 0.03 | -0.853 | 0.37 | 0.383 | 0.71 |
| -1.833 | 0.04 | -0.851 | 0.38 | 0.400 | 0.72 |
| -1.774 | 0.05 | -0.819 | 0.39 | 0.482 | 0.73 |
| -1.767 | 0.06 | -0.805 | 0.40 | 0.518 | 0.74 |
| -1.712 | 0.07 | -0.778 | 0.41 | 0.549 | 0.75 |
| -1.664 | 0.08 | -0.777 | 0.42 | 0.551 | 0.76 |
| -1.556 | 0.09 | -0.751 | 0.43 | 0.926 | 0.77 |
| -1.527 | 0.10 | -0.740 | 0.44 | 0.980 | 0.78 |
| -1.509 | 0.11 | -0.712 | 0.45 | 0.999 | 0.79 |
| -1.365 | 0.12 | -0.636 | 0.46 | 1.238 | 0.80 |
| -1.351 | 0.13 | -0.593 | 0.47 | 1.316 | 0.81 |
| -1.308 | 0.14 | -0.579 | 0.48 | 1.373 | 0.82 |
| -1.242 | 0.15 | -0.572 | 0.49 | 1.384 | 0.83 |
| -1.240 | 0.16 | -0.510 | 0.50 | 1.554 | 0.84 |
| -1.181 | 0.17 | -0.499 | 0.51 | 1.816 | 0.85 |
| -1.175 | 0.18 | -0.448 | 0.52 | 2.244 | 0.86 |
| -1.164 | 0.19 | -0.362 | 0.53 | 2.377 | 0.87 |
| -1.158 | 0.20 | -0.218 | 0.54 | 2.607 | 0.88 |
| -1.151 | 0.21 | -0.158 | 0.55 | 2.781 | 0.89 |
| -1.097 | 0.22 | -0.135 | 0.56 | 2.835 | 0.90 |
| -1.085 | 0.23 | -0.063 | 0.57 | 4.061 | 0.91 |
| -1.034 | 0.24 | -0.054 | 0.58 | 4.745 | 0.92 |
| -1.032 | 0.25 | -0.047 | 0.59 | 5.617 | 0.93 |
| -1.020 | 0.26 | -0.024 | 0.60 | 5.631 | 0.94 |
| -1.006 | 0.27 | 0.005 | 0.61 | 7.482 | 0.95 |
| -0.979 | 0.28 | 0.028 | 0.62 | 7.968 | 0.96 |
| -0.952 | 0.29 | 0.086 | 0.63 | 8.749 | 0.97 |
| -0.948 | 0.30 | 0.147 | 0.64 | 11.602 | 0.98 |
| -0.934 | 0.31 | 0.192 | 0.65 | 15.956 | 1.00 |
| -0.890 | 0.32 | 0.213 | 0.67 |
Table 4 Diagnostic performance of liverscore at different cutoff points
| Cut off | Sensitivity | Specificity | PPV | NPV |
| 0.30 | 89 | 48 | 58 | 84 |
| 0.40 | 85 | 62 | 64 | 83 |
| 0.70 | 54 | 90 | 82 | 70 |
| 0.80 | 39 | 96 | 89 | 65 |
- Citation: Arain SA, Jamal Q, Omair A. "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C. World J Gastroenterol 2011; 17(41): 4607-4613
- URL: https://www.wjgnet.com/1007-9327/full/v17/i41/4607.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i41.4607
